Suppr超能文献

原发性开角型青光眼滤过术后失败眼应用 PreserFlo 微导管的疗效和安全性:一项回顾性研究。

Efficacy and Safety of PreserFlo MicroShunt After a Failed Trabeculectomy in Eyes with Primary Open-Angle Glaucoma: A Retrospective Study.

机构信息

Department of Surgical and Clinical, Diagnostic and Pediatric Sciences, Section of Ophthalmology, University of Pavia-IRCCS Fondazione Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy.

Centro Italiano Glaucoma, Milan, Italy.

出版信息

Adv Ther. 2021 Aug;38(8):4403-4412. doi: 10.1007/s12325-021-01811-w. Epub 2021 Jul 12.

Abstract

INTRODUCTION

To evaluate the efficacy and safety of PreserFlo MicroShunt in primary open angle glaucoma (POAG) eyes after a single failed trabeculectomy.

METHODS

Retrospective review of POAG eyes with a failed trabeculectomy that underwent PreserFlo MicroShunt implantation from March 2019 to November 2019, in two Italian glaucoma centers. Pre- and postoperative data were collected and compared.

RESULTS

A total of 31 surgeries in 31 patients were reviewed. Mean preoperative IOP and mean preoperative number of medications were 24.12 ± 3.14 mmHg and 3.29 ± 0.64, respectively, and decreased to 12.56 ± 2.64 mmHg and 0.46 ± 0.77 at the 12-month postoperative follow-up visit (p < 0.01). The most frequent adverse events were transient hypotony (6 eyes, 19.3%) and choroidal effusion (3 eyes, 9.6%). In all cases spontaneous resolution was observed, with no intervention.

CONCLUSION

In POAG eyes with a single failed trabeculectomy, the PreserFlo MicroShunt was safe and effective in reducing the IOP after a 12-month follow-up. The PreserFlo MicroShunt may represent a viable choice as a second surgery.

摘要

简介

评估 PreserFlo MicroShunt 在单次失败的小梁切除术治疗原发性开角型青光眼(POAG)眼后的疗效和安全性。

方法

回顾性分析 2019 年 3 月至 2019 年 11 月在意大利的两个青光眼中心接受 PreserFlo MicroShunt 植入术的失败性小梁切除术治疗的 POAG 眼。收集并比较术前和术后数据。

结果

共回顾了 31 例 31 眼手术。平均术前眼压和平均术前用药数分别为 24.12±3.14mmHg 和 3.29±0.64,术后 12 个月随访时分别降至 12.56±2.64mmHg 和 0.46±0.77(p<0.01)。最常见的不良事件是短暂性低眼压(6 眼,19.3%)和脉络膜脱离(3 眼,9.6%)。所有病例均自发缓解,无需干预。

结论

在单次失败的小梁切除术后的 POAG 眼中,PreserFlo MicroShunt 在 12 个月的随访中降低眼压是安全有效的。PreserFlo MicroShunt 可能是作为二次手术的可行选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82eb/8342380/4b37ec3b5a16/12325_2021_1811_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验